头孢克洛分散片

金鸿药业股份有限公司，股票代码：831186，新三板挂牌企业，成立于2005年4月，注册资本6560万元，是一家集药品研发、生产与销售为一体的现代化制药企业，产品涵盖医药中间体、原料药和制剂。金鸿药业以满足患者健康需求为己任，奉行“至善、勤勉、简洁”的经营理念，努力建成国际化的品牌制药企业。金鸿药业现有金海岸和定家湾两个生产园区，占地面积分别为31,670 m2和53,450 m2。金鸿药业现有13个车间25条生产线和29项专利。在药品研发、生产与质量控制方面，金鸿药业一直保持着高标准的质量管理水平。所有药品上市均经过主管机构审评，药品的生产严格按照现行GMP要求，从而保证药品的安全性、质量和有效性。Kinhoo Pharmaceutical Co., Ltd., stock code: 831186, as a NEEQ listed enterprise, found in April 2005 with a registered capital of RMB 65.6 million. Kinhoo is a modernized pharmaceutical enterprise integrating pharmaceutical R&D, production and sales, engaged with medical intermediates, active pharmaceutical ingredients (APIs) and pharmaceutical preparations. To meet health needs of patients, Kinhoo holds the business philosophy of “Perfection, Diligence, Concision”, and strives for building an international brand pharmaceutical enterprise. Kinhoo has two Manufacturing Sites, Golden Coast bio-industrial park and Dingjia Bay international medical ecological park, covering an area of 31,670 m2 and 53,450 m2 respectively. Kinhoo has 13 workshops with 25 production lines and 29 patents. Kinhoo maintains high standards of Quality Management in the development, manufacture and control of medicinal products. All medicinal products are assessed by the competent authority to get marketing authorizations, the manufacture of medicinal products has strictly taken place in accordance with guidelines for current Good Manufacturing Practice, to ensure compliance with contemporary requirements of safety, quality and efficacy.